|
|
Post by dreamboatcruise on Oct 2, 2015 17:35:56 GMT -5
It is my understanding that currently any software that would recommend dosing of medications would be subject to lengthy FDA trials almost as if it were a new drug. It's probably easier to develop the technology than get it approved.
|
|
|
|
Post by papihoyos on Oct 3, 2015 12:50:08 GMT -5
What approval is required? Its non-invasive. Do you need FDA approval for a thermometer? The device provides information.
|
|
|
|
Post by tayl5 on Oct 3, 2015 16:33:29 GMT -5
Happy thought for the day. There is a lot of MannKind management bashing in this thread. It's good to remember that these guys likely have a sizable chunk of their personal wealth at stake as well as their salaries. They don't seem particularly concerned about the current situation and they're not doing things that companies under pressure typically do, e.g. frequent press releases. Maybe it's incompetence but maybe they know something that allows them to sleep better at night than we do.
|
|
|
|
Post by xoxoxoxo on Oct 3, 2015 19:15:53 GMT -5
Happy thought for the day. There is a lot of MannKind management bashing in this thread. It's good to remember that these guys likely have a sizable chunk of their personal wealth at stake as well as their salaries. They don't seem particularly concerned about the current situation and they're not doing things that companies under pressure typically do, e.g. frequent press releases. Maybe it's incompetence but maybe they know something that allows them to sleep better at night than we do. Only recently did they quit selling... That was a good sign |
|
|
|
Post by lorcan458 on Nov 18, 2015 10:36:25 GMT -5
Here are the pieces of technology that I would be putting together with Afrezza, with the help of Sanofi, Google Life Sciences and a company with a product like Glucowise. I'd combine non-invasive realtime glucose monitoring that sends data to a phone, an app that allows you to enter what foods you are eating and a smartwatch to monitor exercise activity. All this data is stored and analyzed by Google. Mannkind would develop a smart inhaler that would be able to deliver a precise enough range of doses so that when the app looks at your current blood glucose level and the meal you intend to have, the dose of Afrezza is custom measured. Then, after the meal, the app learns how accurate it's guess was and improvements are made. Google analytics combines everyone's anonymous data to further refine its dosing algorithm. The app would also suggest menu changes, exercise changes, etc. Afrezza being a dry powder and quick acting I think is the ideal mealtime insulin for this type of customized treatment. I believe if the above could be implemented, those diabetics will live very close to normal lives and may even have better control over their blood sugar levels than pre-diabetics. I don't see any technical hurdles to this. It just needs vision and money, as far as I can tell. I just provided the vision, Google and Sanofi have the money. Let's change the world. This is what the Sanofi inhaler is for. |
|
